<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39325919</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-2986</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of global health</Title><ISOAbbreviation>J Glob Health</ISOAbbreviation></Journal><ArticleTitle>The effectiveness of COVID-19 vaccination in preventing hospitalisation and mortality: A nationwide cross-sectional study in Iran.</ArticleTitle><Pagination><StartPage>05026</StartPage><MedlinePgn>05026</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">05026</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7189/jogh.14.05026</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The pandemic of the coronavirus disease 2019 (COVID-19) led to a global health crisis, prompting widespread vaccination efforts to reduce severe outcomes. In this study, we assessed the impact of mass COVID-19 vaccination on hospitalisation and mortality rates in Iran, where over 83% of the vaccinated population received inactivated virus vaccines.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Using retrospective, cross-sectional analysis, we examined data from the Iran Health Insurance Organisation, covering 41 million individuals from 20 February 2020 to 20 March 2022. We analysed hospital records from 956 Iranian hospitals, focusing on inpatient stays, short-term hospitalisations, and emergency department visits. Study outcomes included COVID-19 hospital admissions and associated mortality. We used negative binomial regression to compare hospital admission rates between periods, while we used a poison regression model with a log link to assess mortality risks before and after vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among 806 076 hospital admissions, 57 599 deaths were recorded. COVID-19 hospitalisations increased with age, and women had slightly higher admission rates than men. Advanced age and male sex correlated with higher mortality rates. Hospital admissions rose to 1178.66 per million population per month post-vaccination compared to 459.78 pre-vaccination. The incidence rate ratio was 2.09 (95% confidence interval (CI) = 1.90-2.32, P &lt; 0.001), mainly due to the Delta variant. In contrast, post-vaccination mortality rates decreased from 111.33 to 51.66 per 1000 admissions per month. Post-vaccination, COVID-19 mortality significantly decreased, with a relative risk being 0.61 (95% CI = 0.60-0.62, P &lt; 0.001) across all age groups and sexes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The Delta variant increased hospital admissions among vaccinated individuals, but widespread vaccination significantly reduced COVID-19-related mortality.</AbstractText><CopyrightInformation>Copyright © 2024 by the Journal of Global Health. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Razimoghadam</LastName><ForeName>Mahya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daroudi</LastName><ForeName>Rajabali</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Center for Health Insurance Research, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaseri</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>J Glob Health</MedlineTA><NlmUniqueID>101578780</NlmUniqueID><ISSNLinking>2047-2978</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose no relevant interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>14</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39325919</ArticleId><ArticleId IdType="pmc">PMC11426934</ArticleId><ArticleId IdType="doi">10.7189/jogh.14.05026</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. WHO coronavirus (COVID-19) dashboard. 2024. Available: https://data.who.int/dashboards/covid19/cases?n=c. Accessed: 4 September 2024.</Citation></Reference><Reference><Citation>Jara A, Undurraga EA, Flores JC, Zubizarreta JR, González C, Pizarro A, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study. Lancet Reg Health Am. 2023;21:100487. 10.1016/j.lana.2023.100487</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2023.100487</ArticleId><ArticleId IdType="pmc">PMC10117174</ArticleId><ArticleId IdType="pubmed">37155483</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichaidit M, Nopsopon T, Sunan K, Phutrakool P, Ruchikachorn P, Wanvarie D, et al. Breakthrough infections, hospital admissions, and mortality after major COVID-19 vaccination profiles: A prospective cohort study. Lancet Reg Health Southeast Asia. 2023;8:100106. 10.1016/j.lansea.2022.100106</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lansea.2022.100106</ArticleId><ArticleId IdType="pmc">PMC9633626</ArticleId><ArticleId IdType="pubmed">36349259</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos CVBD, Noronha TG, Werneck GL, Struchiner CJ, Villela DAM.Estimated COVID-19 severe cases and deaths averted in the first year of the vaccination campaign in Brazil: A retrospective observational study. Lancet Reg Health Am. 2023;17:100418. 10.1016/j.lana.2022.100418</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100418</ArticleId><ArticleId IdType="pmc">PMC9779315</ArticleId><ArticleId IdType="pubmed">36575682</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira LS, Darcie Marquitti FM, Paixão da Silva RL, Borges ME, Ferreira da Costa Gomes M, Cruz OG, et al. Estimating the impact of implementation and timing of the COVID-19 vaccination programme in Brazil: a counterfactual analysis. Lancet Reg Health Am. 2023;17:100397. 10.1016/j.lana.2022.100397</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100397</ArticleId><ArticleId IdType="pmc">PMC9676113</ArticleId><ArticleId IdType="pubmed">36439909</ArticleId></ArticleIdList></Reference><Reference><Citation>Danza P, Koo TH, Haddix M, Fisher R, Traub E, OYong K, et al. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:177–81. 10.15585/mmwr.mm7105e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7105e1</ArticleId><ArticleId IdType="pmc">PMC8812833</ArticleId><ArticleId IdType="pubmed">35113851</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Huang H, Ju J, Sun R, Zhang J.Impact of vaccination on the COVID-19 pandemic in U.S. states. Sci Rep. 2022;12:1554. 10.1038/s41598-022-05498-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-05498-z</ArticleId><ArticleId IdType="pmc">PMC8799714</ArticleId><ArticleId IdType="pubmed">35091640</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatzilena A, Hyams C, Challen R, Marlow R, King J, Adegbite D, et al. Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: A prospective test negative case-control study. Lancet Reg Health Eur. 2022;25:100552. 10.1016/j.lanepe.2022.100552</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100552</ArticleId><ArticleId IdType="pmc">PMC9728025</ArticleId><ArticleId IdType="pubmed">36506791</ArticleId></ArticleIdList></Reference><Reference><Citation>Suthar AB, Wang J, Seffren V, Wiegand RE, Griffing S, Zell E.Public health impact of covid-19 vaccines in the US: observational study. BMJ. 2022;377:e069317. 10.1136/bmj-2021-069317</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069317</ArticleId><ArticleId IdType="pmc">PMC9044401</ArticleId><ArticleId IdType="pubmed">35477670</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin JM, Khan F, Pugh S, Swerdlow DL, Jodar L.County-level vaccination coverage and rates of COVID-19 cases and deaths in the United States: An ecological analysis. Lancet Reg Health Am. 2022;9:100191. 10.1016/j.lana.2022.100191</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100191</ArticleId><ArticleId IdType="pmc">PMC8802692</ArticleId><ArticleId IdType="pubmed">35128511</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilches TN, Sah P, Moghadas SM, Shoukat A, Fitzpatrick MC, Hotez PJ, et al. COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA. Lancet Reg Health Am. 2022;6:100147. 10.1016/j.lana.2021.100147</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2021.100147</ArticleId><ArticleId IdType="pmc">PMC8714489</ArticleId><ArticleId IdType="pubmed">34977848</ArticleId></ArticleIdList></Reference><Reference><Citation>Leshem E, Nelson K, Lopman BA.Severe breakthrough COVID-19 infections in Scotland-implications for immunisation programmes. Lancet Respir Med. 2021;9:1354–6. 10.1016/S2213-2600(21)00413-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00413-6</ArticleId><ArticleId IdType="pmc">PMC8480960</ArticleId><ArticleId IdType="pubmed">34599904</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornforth F, Webber L, Kerr G, Dinsdale H, Majeed A, Greengross P.Impact of COVID-19 vaccination on COVID-19 hospital admissions in England during 2021: an observational study. J R Soc Med. 2023;116:167–76. 10.1177/01410768231157017</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768231157017</ArticleId><ArticleId IdType="pmc">PMC10248539</ArticleId><ArticleId IdType="pubmed">36825557</ArticleId></ArticleIdList></Reference><Reference><Citation>Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, et al. COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022. JAMA Intern Med. 2022;182:1071–81. 10.1001/jamainternmed.2022.4299</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2022.4299</ArticleId><ArticleId IdType="pmc">PMC9459904</ArticleId><ArticleId IdType="pubmed">36074486</ArticleId></ArticleIdList></Reference><Reference><Citation>Stepanova M, Lam B, Younossi E, Felix S, Ziayee M, Price J, et al. The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19. BMC Infect Dis. 2022;22:702. 10.1186/s12879-022-07657-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07657-z</ArticleId><ArticleId IdType="pmc">PMC9394045</ArticleId><ArticleId IdType="pubmed">35996076</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan PD, Charlett A, Birrell P, Elgohari S, Hope R, Mandal S, et al. Trends in COVID-19 hospital outcomes in England before and after vaccine introduction, a cohort study. Nat Commun. 2022;13:4834. 10.1038/s41467-022-32458-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32458-y</ArticleId><ArticleId IdType="pmc">PMC9382625</ArticleId><ArticleId IdType="pubmed">35977938</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamara LA, Wiegand RE, Burke RM, Sharma AJ, Sheppard M, Adjemian J, et al. Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data. Lancet. 2022;399:152–60. 10.1016/S0140-6736(21)02226-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02226-1</ArticleId><ArticleId IdType="pmc">PMC8565933</ArticleId><ArticleId IdType="pubmed">34741818</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA bnt162b2 vaccine against sars-cov-2 infections and covid-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data. Lancet. 2021;397:1819–29. 10.1016/S0140-6736(21)00947-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00947-8</ArticleId><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the chadox1 ncov-19 vaccine (azd1222) against sars-cov-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. 10.1016/S0140-6736(20)32661-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Niessen FA, Knol MJ, Hahné SJM, VECTOR study group Bonten MJM, Bruijning-Verhagen PCJL. Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands: A test-negative case-control study. Vaccine. 2022;40:5044–9. 10.1016/j.vaccine.2022.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.06.011</ArticleId><ArticleId IdType="pmc">PMC9174354</ArticleId><ArticleId IdType="pubmed">35863935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikora D, Rzymski P.COVID-19 Vaccination and Rates of Infections, Hospitalizations, ICU Admissions, and Deaths in the European Economic Area during Autumn 2021 Wave of SARS-CoV-2. Vaccines (Basel). 2022;10:437. 10.3390/vaccines10030437</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10030437</ArticleId><ArticleId IdType="pmc">PMC8955952</ArticleId><ArticleId IdType="pubmed">35335069</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SW, Ma D, Davoodian A, Ayutyanont N, Werner B.COVID-19 vaccination decreased COVID-19 hospital length of stay, in-hospital death, and increased home discharge. Prev Med Rep. 2023;32:102152. 10.1016/j.pmedr.2023.102152</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmedr.2023.102152</ArticleId><ArticleId IdType="pmc">PMC9933576</ArticleId><ArticleId IdType="pubmed">36811076</ArticleId></ArticleIdList></Reference><Reference><Citation>van Ewijk CE, Kooijman MN, Fanoy E, Raven SF, Middeldorp M, Shah A, et al. COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021. Euro Surveill. 2022;27:2200217. 10.2807/1560-7917.ES.2022.27.45.2200217</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.45.2200217</ArticleId><ArticleId IdType="pmc">PMC9650707</ArticleId><ArticleId IdType="pubmed">36367011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Lindaas A, Matuska K, Izurieta HS, McEvoy R, Menis M, et al. Real-world Effectiveness of mRNA COVID-19 Vaccines Among US Nursing Home Residents Aged ≥65 Years in the Pre-Delta and High Delta Periods. Open Forum Infect Dis. 2024;11:ofae051. 10.1093/ofid/ofae051</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofae051</ArticleId><ArticleId IdType="pmc">PMC10950043</ArticleId><ArticleId IdType="pubmed">38505296</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarwar MU, Waasia FZ, Aloqbi AA, Alandiyjany M, Alqahtani RM, Hafiz LA, et al. Real-world effectiveness of the inactivated COVID-19 vaccines against variant of concerns: meta-analysis. J Infect Public Health. 2024;17:245–53. 10.1016/j.jiph.2023.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2023.12.005</ArticleId><ArticleId IdType="pubmed">38141544</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Xu S, Liu J, Wu L, Qiu J, Wang N, et al. Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study. Nat Commun. 2023;14:2009. 10.1038/s41467-023-37673-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37673-9</ArticleId><ArticleId IdType="pmc">PMC10086022</ArticleId><ArticleId IdType="pubmed">37037803</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzon A, Palandri L, Uguzzoni F, Cristofor CD, Lozza F, Poluzzi R, et al. Effectiveness of the SARS-CoV-2 Vaccination in Preventing Severe Disease-Related Outcomes: A Population-Based Study in the Italian Province of Bolzano (South Tyrol). Int J Public Health. 2024;69:1606792. 10.3389/ijph.2024.1606792</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/ijph.2024.1606792</ArticleId><ArticleId IdType="pmc">PMC10976940</ArticleId><ArticleId IdType="pubmed">38550269</ArticleId></ArticleIdList></Reference><Reference><Citation>Razimoghadam M, Yaseri M, Effatpanah M, Daroudi R.Changes in emergency department visits and mortality during the COVID-19 pandemic: a retrospective analysis of 956 hospitals. Arch Public Health. 2024;82:5. 10.1186/s13690-023-01234-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13690-023-01234-9</ArticleId><ArticleId IdType="pmc">PMC10785366</ArticleId><ArticleId IdType="pubmed">38216989</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Iran Coronavirus (COVID-19) Statistics. 2023. Available: https://www.who.int/countries/irn. Accessed: 4 September 2024.</Citation></Reference><Reference><Citation>Jamaati H, Karimi S, Ghorbani F, Panahi Y, Hosseini-Baharanchi FS, Hajimoradi M, et al. Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID-19 in the Omicron variant era: A national cohort study in Iran. J Med Virol. 2023;95:e28607. 10.1002/jmv.28607</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28607</ArticleId><ArticleId IdType="pubmed">36815507</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafari M, Hosseinpour S, Rezaee-Zavareh MS, Dascalu S, Rostamian S, Aramesh K, et al. A quantitative evaluation of the impact of vaccine roll-out rate and coverage on reducing deaths: insights from the first 2 years of COVID-19 epidemic in Iran. BMC Med. 2023;21:429. 10.1186/s12916-023-03127-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-03127-8</ArticleId><ArticleId IdType="pmc">PMC10642021</ArticleId><ArticleId IdType="pubmed">37953291</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirahmadizadeh A, Heiran A, Bagheri Lankarani K, Serati M, Habibi M, Eilami O, et al. Effectiveness of Coronavirus Disease 2019 Vaccines in Preventing Infection, Hospital Admission, and Death: A Historical Cohort Study Using Iranian Registration Data During Vaccination Program. Open Forum Infect Dis. 2022;9:ofac177. 10.1093/ofid/ofac177</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac177</ArticleId><ArticleId IdType="pmc">PMC9126490</ArticleId><ArticleId IdType="pubmed">35615300</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidarzadeh A, Amini Moridani M, Khoshmanesh S, Kazemi S, Hajiaghabozorgi M, Karami M.Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study. Int J Infect Dis. 2023;128:212–22. 10.1016/j.ijid.2022.12.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.12.024</ArticleId><ArticleId IdType="pmc">PMC9788848</ArticleId><ArticleId IdType="pubmed">36572376</ArticleId></ArticleIdList></Reference><Reference><Citation>Moradi Hasan-Abad A, Arbabi M, Gilasi H, Motedayyen H.Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population. Int J Immunopathol Pharmacol. 2024;38:3946320241239202. 10.1177/03946320241239202</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03946320241239202</ArticleId><ArticleId IdType="pmc">PMC10946076</ArticleId><ArticleId IdType="pubmed">38494849</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabatabaei SR, Babaie D, Hoseini-Alfatemi SM, Shamshiri A, Karimi A.Determining the coverage and efficacy of the COVID-19 vaccination program at the community level in children aged 12 to 17 in Tehran. GMS Hyg Infect Control. 2024;19:Doc04.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10884833</ArticleId><ArticleId IdType="pubmed">38404412</ArticleId></ArticleIdList></Reference><Reference><Citation>Heydarifard Z, Shafiei-Jandaghi NZ, Safaei M, Tavakoli F, Shatizadeh Malekshahi S.Comparison of clinical outcomes, demographic, and laboratory characteristics of hospitalized COVID-19 patients during major three waves driven by Alpha, Delta, and Omicron variants in Tehran, Iran. Influenza Other Respir Viruses. 2023;17:e13184. 10.1111/irv.13184</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13184</ArticleId><ArticleId IdType="pmc">PMC10410233</ArticleId><ArticleId IdType="pubmed">37565071</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi K, Zadheidar S, Zebardast A, Nejati A, Faraji M, Ghavami N, et al. Genomic surveillance of SARS-CoV-2 strains circulating in Iran during six waves of the pandemic. Influenza Other Respir Viruses. 2023;17:e13135. 10.1111/irv.13135</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13135</ArticleId><ArticleId IdType="pmc">PMC10106497</ArticleId><ArticleId IdType="pubmed">37078070</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavarian J, Nejati A, Salimi V, Shafiei Jandaghi NZ, Sadeghi K, Abedi A, et al. Whole genome sequencing of SARS-CoV2 strains circulating in Iran during five waves of pandemic. PLoS One. 2022;17:e0267847. 10.1371/journal.pone.0267847</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0267847</ArticleId><ArticleId IdType="pmc">PMC9060343</ArticleId><ArticleId IdType="pubmed">35499994</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadadi A, Pirzadeh M, Kazemian S, Ashraf H, Ebrahimi M, Karbalai Saleh S, et al. COVID-19 in Iran: clinical presentations and outcomes in three different surges of COVID-19 infection. Virol J. 2022;19:123. 10.1186/s12985-022-01846-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01846-7</ArticleId><ArticleId IdType="pmc">PMC9321282</ArticleId><ArticleId IdType="pubmed">35883172</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaee E, Amirkafi A, Tehrani-Banihashemi A, SoleimanvandiAzar N, Eshrati B, Rampisheh Z, et al. Adverse effects following COVID-19 vaccination in Iran. BMC Infect Dis. 2022;22:476. 10.1186/s12879-022-07411-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07411-5</ArticleId><ArticleId IdType="pmc">PMC9116064</ArticleId><ArticleId IdType="pubmed">35585518</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi M, Zarei T, Haghpanah S, Azarkeivan A, Naderi M, Matin S, et al. Efficacy and Safety of Sinopharm Vaccine for SARS-CoV-2 and breakthrough infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report. Mediterr J Hematol Infect Dis. 2022;14:e2022026. 10.4084/MJHID.2022.026</Citation><ArticleIdList><ArticleId IdType="doi">10.4084/MJHID.2022.026</ArticleId><ArticleId IdType="pmc">PMC8992638</ArticleId><ArticleId IdType="pubmed">35444764</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavousi M, Rezaei F, Sadighi J, Haeri-Mehrizi AA, Mozafari Kermani R, Rostami R, et al. Correlates of covid-19 vaccination in iranian adults. Payesh (Health Monitor). 2023;22:719–25. 10.61186/payesh.22.6.719</Citation><ArticleIdList><ArticleId IdType="doi">10.61186/payesh.22.6.719</ArticleId></ArticleIdList></Reference><Reference><Citation>Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:1645–53. 10.1016/S1473-3099(21)00319-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00319-4</ArticleId><ArticleId IdType="pmc">PMC8238449</ArticleId><ArticleId IdType="pubmed">34197764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–92. 10.1016/S1473-3099(20)30843-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30843-4</ArticleId><ArticleId IdType="pmc">PMC7832443</ArticleId><ArticleId IdType="pubmed">33217362</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21:39–51. 10.1016/S1473-3099(20)30831-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30831-8</ArticleId><ArticleId IdType="pmc">PMC7561304</ArticleId><ArticleId IdType="pubmed">33069281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilbe JM. Negative binomial regression. Cambridge: Cambridge University Press; 2011.</Citation></Reference><Reference><Citation>Peyravi M, Dehbozorgi M, Ahmadi Marzaleh M.Two-Week Lockdown in Iran Due to COVID-19: Impacts, Challenges, and Recommendations. Disaster Med Public Health Prep. 2022;16:1313–4. 10.1017/dmp.2021.28</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/dmp.2021.28</ArticleId><ArticleId IdType="pmc">PMC8027556</ArticleId><ArticleId IdType="pubmed">33583480</ArticleId></ArticleIdList></Reference><Reference><Citation>Razimoghadam M, Yaseri M, Rezaee M, Fazaeli A, Daroudi R.Non-COVID-19 hospitalization and mortality during the COVID-19 pandemic in Iran: a longitudinal assessment of 41 million people in 2019-2022. BMC Public Health. 2024;24:380. 10.1186/s12889-024-17819-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-024-17819-0</ArticleId><ArticleId IdType="pmc">PMC10840276</ArticleId><ArticleId IdType="pubmed">38317148</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseinzadeh A, Sahab-Negah S, Nili S, Aliyari R, Goli S, Fereidouni M, et al. COVID-19 cases, hospitalizations and deaths after vaccination: a cohort event monitoring study, Islamic Republic of Iran. Bull World Health Organ. 2022;100:474–483. 10.2471/BLT.22.288073</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.22.288073</ArticleId><ArticleId IdType="pmc">PMC9306382</ArticleId><ArticleId IdType="pubmed">35923277</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasergivehchi S, Togha M, Jafari E, Sheikhvatan M, Shahamati D.Headache following vaccination against COVID-19 among healthcare workers with a history of COVID-19 infection: a cross-sectional study in Iran with a meta-analytic review of the literature. Head Face Med. 2023;19:19. 10.1186/s13005-023-00363-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13005-023-00363-4</ArticleId><ArticleId IdType="pmc">PMC10195657</ArticleId><ArticleId IdType="pubmed">37202794</ArticleId></ArticleIdList></Reference><Reference><Citation>Oghazian S, Tavanaei Tamanaei T, Haghighi R, Faregh M, Oghazian MB.Side effects of Sputnik V, Oxford-AstraZeneca, Sinopharm, and Covaxin and their associations with other variables among healthcare workers of a tertiary hospital in Iran. Int Immunopharmacol. 2023;117:109784. 10.1016/j.intimp.2023.109784</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.109784</ArticleId><ArticleId IdType="pmc">PMC9939908</ArticleId><ArticleId IdType="pubmed">36812676</ArticleId></ArticleIdList></Reference><Reference><Citation>Elijah IM, Amsalu E, Jian X, Cao M, Mibei EK, Kerosi DO, et al. Characterization and determinant factors of critical illness and in-hospital mortality of COVID-19 patients: A retrospective cohort of 1,792 patients in Kenya. Biosaf Health. 2022;4:330–8. 10.1016/j.bsheal.2022.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bsheal.2022.06.002</ArticleId><ArticleId IdType="pmc">PMC9236624</ArticleId><ArticleId IdType="pubmed">35782165</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero Starke K, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A.The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021;6:e006434. 10.1136/bmjgh-2021-006434</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-006434</ArticleId><ArticleId IdType="pmc">PMC8678541</ArticleId><ArticleId IdType="pubmed">34916273</ArticleId></ArticleIdList></Reference><Reference><Citation>Rennert-May E, Leal J, Thanh NX, Lang E, Dowling S, Manns B, et al. The impact of COVID-19 on hospital admissions and emergency department visits: A population-based study. PLoS One. 2021;16:e0252441. 10.1371/journal.pone.0252441</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0252441</ArticleId><ArticleId IdType="pmc">PMC8168854</ArticleId><ArticleId IdType="pubmed">34061888</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. BMJ. 2020;369:m1966. 10.1136/bmj.m1966</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1966</ArticleId><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaram SS, Melquist S, Kalgotra P, Srinivasan S, Parasa S, Desai M, et al. Impact of age, sex, race, and regionality on major clinical outcomes of COVID-19 in hospitalized patients in the United States. BMC Infect Dis. 2022;22:659. 10.1186/s12879-022-07611-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07611-z</ArticleId><ArticleId IdType="pmc">PMC9335459</ArticleId><ArticleId IdType="pubmed">35906558</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah SA, Robertson C, Rudan I, Murray JL, McCowan C, Grange Z, et al. Bnt162b2 and chadox1 ncov-19 vaccinations, incidence of sars-cov-2 infections and covid-19 hospitalisations in scotland in the delta era. J Glob Health. 2022;12:05008. 10.7189/jogh.12.05008</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.12.05008</ArticleId><ArticleId IdType="pmc">PMC8942298</ArticleId><ArticleId IdType="pubmed">35356660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsimas D, Lukin G, Mingardi L, Nohadani O, Orfanoudaki A, Stellato B, et al. Covid-19 mortality risk assessment: An international multi-center study. PLoS One. 2020;15:e0243262. 10.1371/journal.pone.0243262</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243262</ArticleId><ArticleId IdType="pmc">PMC7725386</ArticleId><ArticleId IdType="pubmed">33296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanez ND, Weiss NS, Romand J-A, Treggiari MM.Covid-19 mortality risk for older men and women. BMC Public Health. 2020;20:1742. 10.1186/s12889-020-09826-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-09826-8</ArticleId><ArticleId IdType="pmc">PMC7675386</ArticleId><ArticleId IdType="pubmed">33213391</ArticleId></ArticleIdList></Reference><Reference><Citation>Albitar O, Ballouze R, Ooi JP, Sheikh Ghadzi SM.Risk factors for mortality among COVID-19 patients. Diabetes Res Clin Pract. 2020;166:108293. 10.1016/j.diabres.2020.108293</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2020.108293</ArticleId><ArticleId IdType="pmc">PMC7332436</ArticleId><ArticleId IdType="pubmed">32623035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouhpayeh H.Clinical features predicting COVID-19 mortality risk. Eur J Transl Myol. 2022;32:10268. 10.4081/ejtm.2022.10268</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/ejtm.2022.10268</ArticleId><ArticleId IdType="pmc">PMC9295175</ArticleId><ArticleId IdType="pubmed">35421918</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricoca Peixoto V, Vieira A, Aguiar P, Carvalho C, Thomas D, Sousa P, et al. Difference in determinants of ICU admission and death among COVID-19 hospitalized patients in two epidemic waves in Portugal: possible impact of healthcare burden and hospital bed occupancy on clinical management and outcomes, March-December 2020. Front Public Health. 2023;11:1215833. 10.3389/fpubh.2023.1215833</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1215833</ArticleId><ArticleId IdType="pmc">PMC10370276</ArticleId><ArticleId IdType="pubmed">37501943</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Zhong W, Bian Z, Li Z, Zhang K, Liang B, et al. A comparison of mortality-related risk factors of covid-19, sars, and mers: A systematic review and meta-analysis. J Infect. 2020;81:e18–25. 10.1016/j.jinf.2020.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.07.002</ArticleId><ArticleId IdType="pmc">PMC7334925</ArticleId><ArticleId IdType="pubmed">32634459</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikhi F, Yousefian N, Tehranipoor P, Kowsari Z.Estimation of the basic reproduction number of alpha and delta variants of covid-19 pandemic in iran. PLoS One. 2022;17:e0265489. 10.1371/journal.pone.0265489</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0265489</ArticleId><ArticleId IdType="pmc">PMC9113584</ArticleId><ArticleId IdType="pubmed">35580114</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. 2nd Global consultation on sars-cov-2 Variants of Concern on Public Health Interventions. Geneva: World Health Organization; 2021. Available: https://www.who.int/publications/m/item/2nd-global-consultation-on-assessing-the-impact-of-sars-cov-2-variants-of-concern-on-public-health-interventions. Accessed: 4 September 2024.</Citation></Reference><Reference><Citation>Rahimi F, Talebi Bezmin Abadi A.Emergence of the delta plus variant of sars-cov-2 in iran. Gene Rep. 2021;25:101341. 10.1016/j.genrep.2021.101341</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genrep.2021.101341</ArticleId><ArticleId IdType="pmc">PMC8414840</ArticleId><ArticleId IdType="pubmed">34493992</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakibnia P, Ahmadi RH, Fallah F, Ebrahimzadeh F, Dosari AS, Mojtahedi A, et al. Iran as the center of challenges in the middle east for the outbreak of covid-19 delta variant. Iran Red Crescent Med J. 2021;23:e1394.</Citation></Reference><Reference><Citation>Mahase E.Delta variant: What is happening with transmission, hospital admissions, and restrictions? BMJ. 2021;373:n1513. 10.1136/bmj.n1513</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1513</ArticleId><ArticleId IdType="pubmed">34130949</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghaddar M, Radman R, Macreadie I.Severity, pathogenicity and transmissibility of delta and lambda variants of sars-cov-2, toxicity of spike protein and possibilities for future prevention of covid-19. Microorganisms. 2021;9:2167. 10.3390/microorganisms9102167</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9102167</ArticleId><ArticleId IdType="pmc">PMC8540532</ArticleId><ArticleId IdType="pubmed">34683488</ArticleId></ArticleIdList></Reference><Reference><Citation>Arregocés-Castillo L, Fernández-Niño J, Rojas-Botero M, Palacios-Clavijo A, Galvis-Pedraza M, Rincón-Medrano L, et al. Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. Lancet Healthy Longev. 2022;3:e242–52. 10.1016/S2666-7568(22)00035-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(22)00035-6</ArticleId><ArticleId IdType="pmc">PMC8937302</ArticleId><ArticleId IdType="pubmed">35340743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385:585–94. 10.1056/NEJMoa2108891</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2108891</ArticleId><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL.Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. Nat Commun. 2022;13:5736. 10.1038/s41467-022-33378-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33378-7</ArticleId><ArticleId IdType="pmc">PMC9523190</ArticleId><ArticleId IdType="pubmed">36180428</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Kuo HW, Liu YL, Chuang JH, Chou JH.Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan. Emerg Infect Dis. 2024;30:478–89. 10.3201/eid3003.230893</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid3003.230893</ArticleId><ArticleId IdType="pmc">PMC10902541</ArticleId><ArticleId IdType="pubmed">38295401</ArticleId></ArticleIdList></Reference><Reference><Citation>Theresa Pool SN, Shroff EH, Chetty A, Lewis L, Nonhlanhla YZ, Abdool Karim SS.Effectiveness of chadox1 ncov-19 and bbibp-corv vaccines against covid-19-associated hospitalisation and death in the seychelles infected adult population. PLoS One. 2024;19:e0299747. 10.1371/journal.pone.0299747</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0299747</ArticleId><ArticleId IdType="pmc">PMC10997067</ArticleId><ArticleId IdType="pubmed">38578809</ArticleId></ArticleIdList></Reference><Reference><Citation>Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Aghayari Sheikh Neshin S, Khatami A, et al. Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies. Vaccines (Basel). 2021;10:23. 10.3390/vaccines10010023</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010023</ArticleId><ArticleId IdType="pmc">PMC8778641</ArticleId><ArticleId IdType="pubmed">35062684</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang M, Yi Y, Li Y, Sun L, Deng A, Hu T, et al. Effectiveness of inactivated covid-19 vaccines against illness caused by the b.1.617.2 (delta) variant during an outbreak in guangdong, china: A cohort study. Ann Intern Med. 2022;175:533–40. 10.7326/M21-3509</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-3509</ArticleId><ArticleId IdType="pmc">PMC8819853</ArticleId><ArticleId IdType="pubmed">35099990</ArticleId></ArticleIdList></Reference><Reference><Citation>He T, Wang M, Mi H, Xu L, Lu W, Ouyang X, et al. Effectiveness of inactivated vaccine against sars-cov-2 delta variant infection in Xiamen, China—a test-negative case-control study. Vaccines (Basel). 2023;11:532. 10.3390/vaccines11030532</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030532</ArticleId><ArticleId IdType="pmc">PMC10052085</ArticleId><ArticleId IdType="pubmed">36992116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z, Tao B, Li Z, Song Y, Yi C, Li J, et al. Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China. Int J Infect Dis. 2022;116:204–9. 10.1016/j.ijid.2022.01.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.01.030</ArticleId><ArticleId IdType="pmc">PMC8769614</ArticleId><ArticleId IdType="pubmed">35065255</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidari M, Sayfouri N, Jafari H.Consecutive Waves of COVID-19 in Iran: Various Dimensions and Probable Causes. Disaster Med Public Health Prep. 2022;17:e136. 10.1017/dmp.2022.45</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/dmp.2022.45</ArticleId><ArticleId IdType="pmc">PMC9509792</ArticleId><ArticleId IdType="pubmed">35152937</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Ichikawa T, Suzuki S, Tanino Y, Kakinoki Y.Clinical characteristics of the severe acute respiratory syndrome coronavirus 2 omicron variant compared with the delta variant: a retrospective case-control study of 318 outpatients from a single sight institute in Japan. PeerJ. 2022;10:e13762. 10.7717/peerj.13762</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.13762</ArticleId><ArticleId IdType="pmc">PMC9354737</ArticleId><ArticleId IdType="pubmed">35935257</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidari M, Jafari H.Challenges of COVID-19 Vaccination in Iran: In the Fourth Wave of Pandemic Spread. Prehosp Disaster Med. 2021;36:659–60. 10.1017/S1049023X21000777</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1049023X21000777</ArticleId><ArticleId IdType="pmc">PMC8365040</ArticleId><ArticleId IdType="pubmed">34287113</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster P.COVID-19 timeline of events. Nat Med. 2021;27:2054–5. 10.1038/s41591-021-01618-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01618-w</ArticleId><ArticleId IdType="pubmed">34907389</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakhostin-Ansari A, Zimet GD, Khonji MS, Aghajani F, Teymourzadeh A, Rastegar Kazerooni AA, et al. Acceptance or Rejection of the COVID-19 Vaccine: A Study on Iranian People’s Opinions toward the COVID-19 Vaccine. Vaccines (Basel). 2022;10:670. 10.3390/vaccines10050670</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050670</ArticleId><ArticleId IdType="pmc">PMC9143028</ArticleId><ArticleId IdType="pubmed">35632426</ArticleId></ArticleIdList></Reference><Reference><Citation>Maharlouei N, Hosseinpour P, Erfani A, Shahriarirad R, Raeisi Shahrakie H, Rezaianzadeh A, et al. Factors associated with reluctancy to acquire covid-19 vaccination: A cross-sectional study in shiraz, iran, 2022. PLoS One. 2022;17:e0278967 10.1371/journal.pone.0278967</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0278967</ArticleId><ArticleId IdType="pmc">PMC9744289</ArticleId><ArticleId IdType="pubmed">36508442</ArticleId></ArticleIdList></Reference><Reference><Citation>Moini A, Rabiei M, Pirjani R, Abiri A, Maleki-Hajiagha A.COVID-19 vaccine hesitancy among pregnant women and their reported reasons for vaccine refusal - A prospective study in Tehran, Iran. Vaccine. 2023;41:1490–5. 10.1016/j.vaccine.2023.01.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.01.022</ArticleId><ArticleId IdType="pmc">PMC9841077</ArticleId><ArticleId IdType="pubmed">36707338</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghighi H, Takian A, Raoofi A.Institutionalization of Health System to Combat the COVID-19 Pandemic in Iran. Int J Public Health. 2023;68:1606197. 10.3389/ijph.2023.1606197</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/ijph.2023.1606197</ArticleId><ArticleId IdType="pmc">PMC10390691</ArticleId><ArticleId IdType="pubmed">37533683</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamshiri M, Ajri-Khameslou M, Dashti-Kalantar R, Molaei B.Management Strategies During the COVID-19 Pandemic Crisis: The Experiences of Health Managers from Iran, Ardabil Province. Disaster Med Public Health Prep. 2022;17:e140. 10.1017/dmp.2022.51</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/dmp.2022.51</ArticleId><ArticleId IdType="pmc">PMC9002145</ArticleId><ArticleId IdType="pubmed">35241208</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow DA, DeLeo RA, Albright EA, Taylor K, Birkland T, Zhang M, et al. Policy learning and change during crisis: COVID-19 policy responses across six states. Rev Policy Res. 2023;40:10–35. 10.1111/ropr.12511</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ropr.12511</ArticleId><ArticleId IdType="pmc">PMC9874426</ArticleId><ArticleId IdType="pubmed">36714158</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger L, Berger N, Bosetti V, Gilboa I, Hansen LP, Jarvis C, et al. Rational policymaking during a pandemic. Proc Natl Acad Sci U S A. 2021;118:e2012704118. 10.1073/pnas.2012704118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2012704118</ArticleId><ArticleId IdType="pmc">PMC7848715</ArticleId><ArticleId IdType="pubmed">33472971</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdi M.Coronavirus disease 2019 (COVID-19) outbreak in Iran: Actions and problems. Infect Control Hosp Epidemiol. 2020;41:754–5. 10.1017/ice.2020.86</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2020.86</ArticleId><ArticleId IdType="pmc">PMC7137533</ArticleId><ArticleId IdType="pubmed">32192541</ArticleId></ArticleIdList></Reference><Reference><Citation>Khankeh H, Farrokhi M, Roudini J, Pourvakhshoori N, Ahmadi S, Abbasabadi-Arab M, et al. Challenges to manage pandemic of coronavirus disease (covid-19) in iran with a special situation: A qualitative multi-method study. BMC Public Health. 2021;21:1919. 10.1186/s12889-021-11973-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-11973-5</ArticleId><ArticleId IdType="pmc">PMC8532398</ArticleId><ArticleId IdType="pubmed">34686165</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadinia L, Saadatmand V, Khaledi Sardashti H, Darabi S, Esfandiary Bayat F, Rejeh N, et al. Hospital response challenges and strategies during COVID-19 pandemic: a qualitative study. Front Public Health. 2023;11:1167411. 10.3389/fpubh.2023.1167411</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1167411</ArticleId><ArticleId IdType="pmc">PMC10349376</ArticleId><ArticleId IdType="pubmed">37457272</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon DE, Peters GA, Ivers LC, Freeman EE.Global resource shortages during COVID-19: Bad news for low-income countries. PLoS Negl Trop Dis. 2020;14:e0008412. 10.1371/journal.pntd.0008412</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0008412</ArticleId><ArticleId IdType="pmc">PMC7337278</ArticleId><ArticleId IdType="pubmed">32628664</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Soe MM, Konnor R, Dantes R, Haass K, Dudeck MA, et al. Hospital capacities and shortages of healthcare resources among US hospitals during the coronavirus disease 2019 (COVID-19) pandemic, National Healthcare Safety Network (NHSN), March 27-July 14, 2020. Infect Control Hosp Epidemiol. 2022;43:1473–6. 10.1017/ice.2021.280</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2021.280</ArticleId><ArticleId IdType="pmc">PMC8280389</ArticleId><ArticleId IdType="pubmed">34167599</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulholland RH, Wood R, Stagg HR, Fischbacher C, Villacampa J, Simpson CR, et al. Impact of covid-19 on accident and emergency attendances and emergency and planned hospital admissions in scotland: An interrupted time-series analysis. J R Soc Med. 2020;113:444–53. 10.1177/0141076820962447</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0141076820962447</ArticleId><ArticleId IdType="pmc">PMC7686524</ArticleId><ArticleId IdType="pubmed">33012218</ArticleId></ArticleIdList></Reference><Reference><Citation>Nab L, Parker EPK, Andrews CD, Hulme WJ, Fisher L, Morley J, et al. Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. Lancet Public Health. 2023;8:e364–77. 10.1016/S2468-2667(23)00079-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(23)00079-8</ArticleId><ArticleId IdType="pmc">PMC10139026</ArticleId><ArticleId IdType="pubmed">37120260</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>